Company: CERO
Filing Date: 2025-09-05
Form Type: 424B3
Source: 0001213900-25-085127
Chunk: 5

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-09-05
Form: 424B3
Chunk 5
---
 words such as “anticipate,” “believe,” “continue,”
“could,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “strive,”
“would” and similar expressions may identify forward-looking statements, but the absence of these words does not mean that
a statement is not forward-looking. When CERo discusses its strategies or plans, it is making projections, forecasts or forward-looking
statements. Such statements are based on the beliefs of, as well as assumptions made by and information currently available to, CERo’s
management.

Actual results could differ from those implied by the forward-looking
statements in this communication. Certain risks that could cause actual results to differ are set forth in CERo’s filings with the
Securities and Exchange Commission, including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q,
and the documents incorporated by reference therein. The risks described in CERo’s filings with the Securities and Exchange Commission
are not exhaustive. New risk factors emerge from time to time, and it is not possible to predict all such risk factors, nor can CERo assess
the impact of all such risk factors on its business, or the extent to which any factor or combination of factors may cause actual results
to differ materially from those contained in any forward-looking statements. Forward-looking statements are not guarantees of performance.
You should not put undue reliance on these statements, which speak only as of the date hereof. All forward-looking statements made by
CERo or persons acting on its behalf are expressly qualified in their entirety by the foregoing cautionary statements. CERo undertakes
no obligation to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.

Contact:

Chris Ehrlich
Chief Executive Officer
chris@cero.bio

Investors:

CORE IR
investors@cero.bio